Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
Holding ZTS?
Track your performance easily
ZTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$144.80 - $200.89
Previous Close$179.04
Volume2.22M
Average Volume (3M)2.84M
Market Cap
$81.70B
Enterprise Value$88.44B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.75B
Price to Earnings (P/E)34.5
Beta1.24
Next Earnings
Aug 06, 2024EPS Estimate
$1.49Last Dividend Ex-Date
Jul 18, 2024Dividend Yield0.9%
Share Statistics
EPS (TTM)5.19
Shares Outstanding456,295,137
10 Day Avg. Volume2,494,965
30 Day Avg. Volume2,841,240
Standard Deviation0.07
R-Squared0.40
Alpha0.00108
Financial Highlights & Ratios
Price to Book (P/B)15.63
Price to Sales (P/S)9.14
Price to Cash Flow (P/CF)21.80
P/FCF Ratio26.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.35
Enterprise Value/Gross Profit14.78
Enterprise Value/Ebitda24.13
Forecast
1Y Price Target
$211.00Price Target Upside18.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Zoetis News
PremiumCompany Announcements
Zoetis Reports Strong Q3 2024 Financial Results
PremiumPre-Earnings
Zoetis (ZTS) Q3 Earnings Cheat Sheet
PremiumCompany Announcements
Zoetis Announces Q4 Dividend; Cautions on Future Uncertainties
Bulls Say, Bears Say
Bulls Say
InnovationGreater conviction in ZTS's long-term prospects, innovation drivers, and competitive positioning, fueling above-market growth.
Product PerformanceManagement is pleased with Librela's performance in both the US and international markets, citing a steady increase in sales.
Regulatory ConfidenceManagement emphasized that its level of engagement with the FDA is normal, indicating confidence in regulatory compliance.
Bears Say
Operational ExpensesHigher operational expenses are expected to be at the high-end of guidance.
Product ExpectationsForecasts for dermatology and parasiticide franchises were raised but offset by lower expectations for MFAs and 'Other' Pharma products.
Sentiment And Stock PriceRecent negative sentiment and a significant stock price drop are attributed to escalated concerns regarding Librela's adverse event profile.
---
Ownership Overview
9.33% Insiders
27.60% Mutual Funds
20.26% Other Institutional Investors
42.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $144.80 and its highest was $200.89 in the past 12 months.
What is Zoetis’s market cap?
Currently, no data Available
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Aug 06, 2024 which is 94 days ago.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on May 02, 2024. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.346 by $0.034.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 0.9%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is $1.49.
How many shares outstanding does Zoetis have?
Zoetis has 456,295,140 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.38 in its last earnings report, beating expectations of $1.346. Following the earnings report the stock price went up 5.508%.
Which hedge fund is a major shareholder of Zoetis?
Among the largest hedge funds holding Zoetis’s share is Intermede Investment Partners Ltd. It holds Zoetis’s shares valued at 156M.
---
Zoetis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$211.00 (18.55% Upside)
$211.00 (18.55% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 95%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 245.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.19%
12-Months-Change
Fundamentals
Return on Equity
50.06%
Trailing 12-Months
Asset Growth
4.32%
Trailing 12-Months
Company Description
Zoetis
Founded in 1952, New Jersey-based Zoetis, Inc. is the world's largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.
---
ZTS Company Deck
---
ZTS Earnings Call
Q1 2024
0:00 / 0:00
---
ZTS Revenue Breakdown
22.79% Parasiticides
20.73% Vaccines
16.70% Dermatology
14.98% Other pharmaceuticals
24.80% Other
---
ZTS Stock 12 Month Forecast
Average Price Target
$211.00
▲(18.55% Upside)
Technical Analysis
Best Analysts Covering ZTS
1 Year
1 Year Success Rate
17/18 ratings generated profit
1 Year Average Return
+23.51%
assigned a buy rating 4 months ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +23.51% per trade.
---